Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Oncology·MeSH: Blastic Plasmacytoid Dendritic Cell Neoplasm
Prevalence
30.0 / 100K
4 drugs in development·3 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| elzonris | STEMLINE THERAPEUTICS INC (STML) |
Phase 2(2)
BLA Filed(1)
| Drug | Company |
|---|---|
| sl-401 | STEMLINE THERAPEUTICS INC (STML) |
Compare drugs
Frequently asked questions
How many drugs are in development for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)?
BioSniper tracks 4 drugs in development for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) across 3 companies.
How many clinical trials target Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)?
There are 2 clinical trials targeting Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) tracked by BioSniper.
What is the prevalence of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)?
The estimated prevalence of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is approximately 30.0 per 100,000 population.
Deep-dive into Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis